Breno Moreno de Gusmão

Hematologist | BP São Paulo, Brazil
Myeloma · Amyloidosis · Cell Therapy · Clinical Research
Sharing data that matters

[Breno Moreno de Gusmão @morenodegusmao]

🧬 AL Amyloidosis at #EHA2026 — what's new?

✅ Dara-VCd → frontline std
✅ Anselamimab → anti-fibril, AL kappa
✅ NXC-201 CAR-T → responses in frail/cardiac pts 🔥
✅ Bispecifics (teclistamab/elranatamab) → r/r

Treat deep. Save the heart 🫀
#ALAmyloidosis #CART #Bispecific

[Breno Moreno de Gusmão @morenodegusmao]

SUCCESSOR-2 is the late-breaking abstract to watch at #EHA2026. Mezigdomide + Kd showing ORR >80% and mPFS doubling in anti-CD38/IMiD-exposed RRMM. If these data hold, salvage sequencing changes.

[Toru Miyajima, MD @tom1006001]

EHA 2026 Late-Breaking Abstracts: Key Highlights (Personally)
1. SUCCESSOR-2: Mezigdomide + Kd vs Kd in anti-CD38/LEN-exposed RRMM. mPFS 18.0 vs 8.3 months (HR 0.48), ORR 80.2% vs 53.4%, ≥CR 26.7% vs 8.9%. Higher rates of neutropenia and infections, but few grade 5 infections.

[Breno Moreno de Gusmão @morenodegusmao]

The mSMART algorithm continues to evolve rapidly. Bispecifics are now a frontline option in first relapse — the sequencing question is no longer theoretical. Worth internalizing before #EHA2026.

[Vincent Rajkumar @VincentRK]

Based on the latest data at #ASCO26 awe can consider bispecifics especially teclistamab (has the most data) alone or in combination with daratumumab in first relapse of myeloma.

Here is our latest https://t.co/x9KJzoJyXJ approach to first relapse.

[Breno Moreno de Gusmão @morenodegusmao]

This is shaping up to be one of the most compelling EHA meetings in recent years — with robust data across multiple disease areas that will very likely reshape how we treat our patients. Worth following closely.

#Hematology #AML #Myeloma #Lymphoma #Amyloidosis #BMT

[Breno Moreno de Gusmão @morenodegusmao]

#EHA2026 begins next week in Stockholm — and several presentations carry genuine practice-changing potential.

A brief overview of what deserves your attention 🧵👇

[Breno Moreno de Gusmão @morenodegusmao]

🤖 AI in Hematology: A dedicated session will critically examine the practical and ethical integration of artificial intelligence in clinical hematology and oncology.

The question is no longer theoretical.

[Breno Moreno de Gusmão @morenodegusmao]

🇪🇸

[Breno Moreno de Gusmão @morenodegusmao]

Important data to high risk myeloma patients. #EHA2024

[Breno Moreno de Gusmão @morenodegusmao]

Important data by meta-analysis : Quadruplet therapy, improves PFS (HR: 0.63), ORR (OR: 1.7-1.91), and MRDneg (OR: 2.59) in transplant-eligible NDMM patients. However,it increases infection risk (OR: 1.2) and thrombocytopenia (OR: 1.41)#ASCO2024 #mmsm
Abstract 237805

[Breno Moreno de Gusmão @morenodegusmao]

Nodular #amyloidosis on the nose is a rarest type of localized cutaneous amyloidosis. How would you treat? #mmsm

[Breno Moreno de Gusmão @morenodegusmao]

Estou participando de uma imersão de 2 dias na Mayo Clinic, nos Estados Unidos, um dos melhores hospitais do mundo!

Tenho aprendido com a experiência local em manejo clínico e pesquisa clínica com anticorpos biespecíficos e car-t cell para mieloma múlti…https://t.co/bJCPUm0ZX0

[Breno Moreno de Gusmão @morenodegusmao]

@pebarba @vallhebron @Hemato_Vhebron @Sidnavigare Congrats Pere !

[Breno Moreno de Gusmão @morenodegusmao]

Un placer reunir los amigos/ experts para discutir sobre las novedades del mieloma múltiplo.
#mmsm @hemo_meeting @MDHealth_BR @gelamm_latam @GELL01433166 @BrasilOncologia @mvmateos @End_myeloma @humbertomarcor1

[Breno Moreno de Gusmão @morenodegusmao]

Excellent discussion about prognostic factors and treatment of acute lymphoblastic leukemia. @DrMarcosdelima @hemo_meeting @BrasilOncologia @MDHealth_BR @GlamSMD @GELL01433166

[Breno Moreno de Gusmão @morenodegusmao]

Un placer recibir los amigos Adolfo de la Fuente 🇪🇸y Alicia Enrico 🇦🇷en el 2º foro de actualización en oncohematología ! #mds @GlamSMD